GlassScriptPhysician profile
Marilyn Miller
NPI 1649200585
$6,242.69
in general payments reported to CMS, 2019-2025
36 companies · $1,410 in 2025
The $1,410 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $426 · 2022: $1,084 · 2023: $1,609 · 2024: $1,714 · 2025: $1,410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,733.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,732.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,439.38 | 2021-2025 | |
| Glaxosmithkline, LLC. | $677.91 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $616.49 | 2021-2025 | Jardiance |
| Amgen INC. | $372.96 | 2023-2025 | Evenity, Prolia, Otezla |
| Lilly USA, LLC | $304.59 | 2023-2025 | Mounjaro, Zepbound, Emgality |
| Pfizer INC. | $295.31 | 2021-2025 | |
| Astellas Pharma US INC | $282.90 | 2021-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $227.73 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $214.28 | 2022-2025 | Xifaxan |
| Dexcom, INC. | $208.20 | 2024-2025 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $149.93 | 2023-2025 | Gemtesa |
| Astrazeneca Pharmaceuticals LP | $146.45 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $139.13 | 2021-2025 | Trintellix |
| Lundbeck LLC | $135.70 | 2023-2025 | Rexulti |
| Aimmune Therapeutics, INC. | $129.79 | 2024-2025 | Zenpep |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $123.10 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $92.12 | 2021-2025 | Wegovy |
| Janssen Pharmaceuticals, INC | $79.98 | 2021-2023 | Xarelto |
| Esperion Therapeutics, INC. | $61.21 | 2024 | Nexletol |
| Novartis Pharmaceuticals Corporation | $55.97 | 2022-2023 | |
| Axsome Therapeutics, INC. | $55.08 | 2024-2025 | Auvelity |
| Indivior INC. | $49.87 | 2024-2025 | Sublocade |
| Kowa Pharmaceuticals America, INC. | $49.54 | 2022-2023 | Seglentis, Livalo |
| Merck Sharp & Dohme LLC | $43.88 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Otsuka America Pharmaceutical, INC. | $43.65 | 2021-2024 | Rexulti |
| Ucb, INC. | $40.29 | 2023 | Nayzilam |
| Alkermes, INC. | $31.36 | 2022-2025 | Aristada, Lybalvi |
| Phathom Pharmaceuticals, INC. | $29.85 | 2024-2025 | Voquezna |
| Dynavax Technologies Corporation | $24.12 | 2025 | Heplisav-B |
| Endo Pharmaceuticals INC. | $19.63 | 2021 | |
| Xeris Pharmaceuticals, INC. | $19.50 | 2024 | Gvoke Hypopen |
| Ibsa Pharma INC. | $18.71 | 2024 | Tirosint, Licart |
| Shield Therapeutics INC | $18.03 | 2025 | |
| Ironwood Pharmaceuticals, INC | $16.95 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.92 | 2023 | Eliquis |
| Mylan Specialty L.P. | $14.18 | 2024 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marilyn Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.